Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8458853 | Radiotherapy and Oncology | 2018 | 7 Pages |
Abstract
The preferred dose-dependent AR model predicts that, for standard fractionation schemes currently used to treat HNC, the final week (5 fractions) could be eliminated without compromising TCP, but resulting in significantly decreased late sequelae due to the lower overall dose.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Igor Shuryak, Eric J. Hall, David J. Brenner,